Julphar launches two medicines for Type 2 diabetes
DUBAI, October 13, 2016
The UAE-based pharmaceutical manufacturer Julphar Gulf Pharmaceutical Industries has launched two new medications for the management of Type 2 diabetes -- Xelevia and Velmetia.
The launch is part of Julphar’s licence, supply and co-marketing agreement signed in April 2014 with global pharmaceutical leader Merck Sharp & Dohme (MSD).
During a conference to introduce the products, 150 invited doctors had the opportunity to hear speakers Dr Abdul Razzaq Al Madani, consultant endocrinologist and president of the Emirates Diabetes Society; and Prof Eberhard Standl, professor of medicine, specialising in endocrinology and angiology, at the Munich Diabetes Research Group at Helmholtz Centre, address the diabetes burden in the Middle East and present the role and cardiovascular safety of sitagliptin in the management of Type 2 diabetes.
“The launch of Xelevia and Velmetia is part of our continuing mission to develop Julphar diabetes portfolio, to support healthcare community in the region,” said Dr Hosam Badr, marketing director at Julphar.
Both Xelevia (sitagliptin), a plain Dipeptidyl Peptidase 4 (DPP4) – Inhibitor, and Velmetia (sitagliptin and metformin), a fixed dose combination, are used to control Type 2 diabetes in adult patients.
Under the terms of this License and Supply Agreement, MSD grants Julphar exclusive rights to commercialise and distribute five MSD second brands in the areas of diabetes, asthma, allergy, pain and inflammation across the UAE, Kuwait, Bahrain, Oman, Qatar and Iraq. - TradeArabia News Service